Bond.az White LogoBond.az Black Logo

ThinkEquity Initiates Atlas with Buy

ThinkEquity initiates Atlas Technical Consultants with a Buy rating and $15 target. The firm highlights the value of the Brazil critical-minerals option.

Robert Moore
ByRobert Moore- Senior Editor
|
0

ThinkEquity initiated coverage on Atlas Technical Consultants Inc. (NASDAQ:ATCX) with a Buy rating and a $15.00 price target.

The firm bases its rating on an asymmetry between current enterprise value and three probability-adjusted technical paths: Alto Paranaíba rare earths/titanium, Malacacheta graphite, and Rio Piracicaba iron ore cash offset. At a $4.34 reference price and roughly 5.0 million basic shares, market cap is about $21.7 million. The stock trades at $4.44, near its 52-week low of $4.28, reflecting a sharp decline in investor sentiment.

The January offering provided $9.7 million net after Atlas sold 1.38 million shares at $8.00. That funding supports the next exploration cycle but does not make assets development-ready or remove future capital needs if drilling, metallurgy, and option exercise advance simultaneously.

Atlas reported 2025 revenue of $92,491 vs. $667,131 in 2024, gross loss of $59,431 vs. gross profit of $265,694, and net loss of $5.420 million vs. $1.713 million. The gross profit margin stands at negative 64%, highlighting operational challenges.

ThinkEquity values the equity through a risked asset-option sum-of-the-parts approach. For deeper analysis, Bond.az offers 15 additional tips and comprehensive financial health metrics.

More News
Today / 11:03
|
631

Jefferies Raises SentinelOne Price Target to $24

Jefferies raised SentinelOne price target to $24 on margin outlook, maintaining Buy rating. Stock at $18.71, NNARR growth expected. Analyst sees H2 margin expansion.

0
Today / 11:00
|
941

Reddit Stock Rating Boosted by App Growth

Citizens maintains Market Outperform on Reddit stock with $240 target. App installs surged 129% YoY, driving advertising growth.

0
Today / 10:33
|
492

Wolfe Research Reaffirms Ionis Stock Outperform Rating

Wolfe Research reiterates Outperform rating on Ionis Pharmaceuticals stock. Analysis of Arrowhead competition and financial results.

0
Today / 10:31
|
510

BTIG reiterates Uber Buy rating after Delivery Hero bid

BTIG reaffirms Uber Buy rating with $100 target after Delivery Hero bid. Stock seen as undervalued.

0
Today / 10:30
|
550

BTIG Reiterates Neutral on Affirm Stock

BTIG reiterates Neutral on Affirm stock amid credit trends. Analysis of delinquencies, growth prospects, and analyst targets.

0
Today / 10:02
|
707

Mizuho Cuts Intuit Target on TurboTax Weakness

Mizuho cuts Intuit target to $500 on TurboTax weakness; shares fall 20%. Read more on Bond.az.

0
Today / 08:00
|
677

Leerink Reaffirms Eli Lilly Stock Rating on Gene Therapy

Leerink reaffirms Eli Lilly stock rating with Outperform and $1,119 target, citing promising gene therapy data from VERVE-102 trial. Bond.az covers the latest.

0
Today / 06:02
|
602

Goldman Sachs Initiates Hemab Buy

Goldman Sachs initiates Hemab Therapeutics with buy rating. Sutacimig and HMB-002 target rare bleeding disorders.

0
Today / 06:01
|
425

Morgan Stanley Initiates Avalyn Pharma with Overweight

Morgan Stanley initiates Avalyn Pharma with Overweight rating and $53 target. The inhaled therapies AP01 and AP02 show promise in pulmonary fibrosis.

0
Today / 06:00
|
496

Goldman Sachs Backs Seaport Stock

Goldman Sachs initiates coverage on Seaport Therapeutics with an Early-Stage Biotech rating. Learn about the company's platform and financials.

0
Yesterday / 15:32
|
644

Jefferies Initiates Avalyn Pharma with Buy

Jefferies initiates Avalyn Pharma with Buy rating and $52 price target. AP01 shows promising efficacy in progressive lung diseases.

0
Yesterday / 15:31
|
924

Jefferies Initiates Pershing Square USA Buy

Jefferies initiates Buy rating on Pershing Square USA (PSUS), highlighting the fund's strategy, discount, and lack of performance fee.

0
...
ThinkEquity Initiates Atlas with Buy | Bond.az